ERBB2 and breast cancer: Neratinib is a more potent inhibitor than the dual EGFR/HER2 tyrosine kinase inhibitor (TKI) Lapatinib, potentiating the cytotoxic effect of trastuzumab in HER2+ breast cancer cell lines [3, 9].